Horizon and Boehringer Ingelheim enter oncology research service collaboration
Horizon Discovery Ltd announced it has signed a research service collaboration agreement with Boehringer Ingelheim. Horizon will support Boehringer Ingelheim’s oncology programs by using its Discovery Toolbox for research projects and profiling of compounds at the hit-to-lead, lead optimization and pre-clinical stages to elucidate their anti-cancer properties and help guide drug discovery programs.
Under the terms of the collaboration, Horizon will evaluate compounds across a broad panel of X-MAN isogenic models and 2D/3D phenotypic assays, and will provide an FTE.
Horizon will also apply its proprietary genome editing technology GENESIS™ to develop human isogenic disease model cell lines, according to Boehringer Ingelheim’s specifications. Using GENESIS, Horizon is able to alter any endogenous gene sequence of human or mammalian cell lines quickly, reliably and without unwanted and confounding genotypes and/or phenotypes. The resulting high quality cell lines accurately model the disease-causing mutations found in patients.
Other news from the department business & finance
